Q-omics provides the consensus-scored PRAMEF22 profile across patient tissues and cancer cell-line models.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Premium analyses for PRAMEF22 — synthetic lethality, tumor antigen, and pembrolizumab response.

View premium →

Cross-omics associations

This table shows molecular features associated with PRAMEF22 in patient tissues and cancer cell lines. In cancer cell lines, PRAMEF22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.

Associated data type	Strength (# associated data)	Lineage of highest associated data
▼shRNA
shRNA	1,266	BONE (281)	view →
RNA	1,264	BONE (519)	view →